![Inge Lues](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Inge Lues worked as Vice President-Global Drug Discovery at Merck KGaA in 2007.
From 2008 to 2018, Lues worked at Vivoryon Therapeutics NV, where she held the position of Chief Development Officer from 2013 to 2018.
Former positions of Inge Lues
| Companies | Position | End |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Chief Tech/Sci/R&D Officer | 30/10/2018 |
| MERCK KGAA | Corporate Officer/Principal | 31/12/2006 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
11
1st degree connections
2
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Vivoryon Therapeutics NV
 Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
- Stock Market
- Insiders
- Inge Lues
